D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 66 Citations 27,955 255 World Ranking 1804 National Ranking 887
Medicine D-index 70 Citations 28,802 279 World Ranking 17344 National Ranking 8828

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

His primary areas of study are Immunology, Chimeric antigen receptor, Antigen, Immunotherapy and T cell. His Immunology research incorporates themes from Cytotoxic T cell and Interleukin 12. His Chimeric antigen receptor study integrates concerns from other disciplines, such as Tumor microenvironment, Oncology and B cell.

The Antigen study combines topics in areas such as Cancer, Internal medicine, Clinical trial and Car t cells. His studies in Immunotherapy integrate themes in fields like CD28, Receptor and T-cell receptor. His research links Cancer research with T cell.

His most cited work include:

  • Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (1499 citations)
  • CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia (1434 citations)
  • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias (926 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Chimeric antigen receptor, Immunology, Cancer research, Antigen and T cell. Renier J. Brentjens studied Chimeric antigen receptor and Adoptive cell transfer that intersect with Hematopoietic stem cell transplantation. In his study, which falls under the umbrella issue of Immunology, Refractory is strongly linked to Oncology.

His biological study spans a wide range of topics, including Car t cells, Leukemia, Immune checkpoint and CD40. His Antigen research incorporates elements of Cancer, Receptor, Antibody and Immune system. The T cell study combines topics in areas such as Molecular biology, CD8, Cell therapy and B cell.

He most often published in these fields:

  • Chimeric antigen receptor (59.32%)
  • Immunology (39.66%)
  • Cancer research (40.34%)

What were the highlights of his more recent work (between 2019-2021)?

  • Chimeric antigen receptor (59.32%)
  • Cancer research (40.34%)
  • Immunotherapy (31.19%)

In recent papers he was focusing on the following fields of study:

Renier J. Brentjens spends much of his time researching Chimeric antigen receptor, Cancer research, Immunotherapy, Antigen and Internal medicine. His Chimeric antigen receptor study combines topics from a wide range of disciplines, such as Receptor, Cytokine, Multiple myeloma and Cell biology. Renier J. Brentjens has researched Cancer research in several fields, including Immune system, Tyrosine-kinase inhibitor, Safety profile, Interleukin 12 and Refractory Mantle Cell Lymphoma.

His work carried out in the field of Immunotherapy brings together such families of science as Tumor microenvironment, Ovarian cancer and Genetic enhancement. His Antigen research is multidisciplinary, incorporating perspectives in Immune checkpoint, T cell and Cell therapy. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Oncology, and often CD19, MEDLINE, Adult Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia.

Between 2019 and 2021, his most popular works were:

  • Engineering strategies to overcome the current roadblocks in CAR T cell therapy. (135 citations)
  • Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. (32 citations)
  • Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. (32 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

Renier J. Brentjens mainly investigates Antigen, Immunotherapy, Chimeric antigen receptor, Internal medicine and Cancer research. His Antigen study combines topics in areas such as Receptor and Multiple myeloma. He specializes in Immunotherapy, namely CAR T-cell therapy.

His Chimeric antigen receptor research includes elements of Salvage therapy, Subsequent Relapse, Diffuse large B-cell lymphoma and Oncology. The study incorporates disciplines such as Proinflammatory cytokine, Interleukin 12, Cytokine secretion and Genetic enhancement in addition to Cancer research. The concepts of his Lymphoma study are interwoven with issues in Chemotherapy, Gastroenterology, White blood cell, Cytopenia and Chimeric Antigen Receptor T-Cell Therapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido.
Science Translational Medicine (2014)

2389 Citations

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Renier J. Brentjens;Marco L. Davila;Isabelle Riviere;Jae Park.
Science Translational Medicine (2013)

2058 Citations

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park;Isabelle Rivière;Mithat Gonen;Xiuyan Wang.
The New England Journal of Medicine (2018)

1663 Citations

The Basic Principles of Chimeric Antigen Receptor Design

Michel Sadelain;Renier Brentjens;Isabelle Rivière.
Cancer Discovery (2013)

1459 Citations

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila.
Blood (2011)

1346 Citations

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Danny N. Khalil;Eric L. Smith;Renier J. Brentjens;Jedd D. Wolchok.
Nature Reviews Clinical Oncology (2016)

1218 Citations

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière.
Nature Biotechnology (2002)

1019 Citations

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Renier J. Brentjens;Jean Baptiste Latouche;Elmer Santos;Francesc Marti.
Nature Medicine (2003)

877 Citations

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Hollie J. Pegram;James C. Lee;Erik G. Hayman;Gavin H. Imperato.
Blood (2012)

735 Citations

Toxicity and management in CAR T-cell therapy.

Challice L Bonifant;Hollie J Jackson;Renier J Brentjens;Kevin J Curran.
Molecular Therapy - Oncolytics (2016)

723 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Renier J. Brentjens

Carl H. June

Carl H. June

University of Pennsylvania

Publications: 155

Gianpietro Dotti

Gianpietro Dotti

University of North Carolina at Chapel Hill

Publications: 120

Stanley R. Riddell

Stanley R. Riddell

University of Washington

Publications: 107

Laurence J.N. Cooper

Laurence J.N. Cooper

The University of Texas MD Anderson Cancer Center

Publications: 96

Malcolm K. Brenner

Malcolm K. Brenner

Baylor College of Medicine

Publications: 94

John Maher

John Maher

King's College London

Publications: 87

Michel Sadelain

Michel Sadelain

Memorial Sloan Kettering Cancer Center

Publications: 82

Stephan A. Grupp

Stephan A. Grupp

Children's Hospital of Philadelphia

Publications: 75

Steven A. Rosenberg

Steven A. Rosenberg

National Institutes of Health

Publications: 70

Helen E. Heslop

Helen E. Heslop

Baylor College of Medicine

Publications: 68

Phillip K. Darcy

Phillip K. Darcy

Peter MacCallum Cancer Centre

Publications: 66

Marcela V. Maus

Marcela V. Maus

Harvard University

Publications: 66

Barbara Savoldo

Barbara Savoldo

University of North Carolina at Chapel Hill

Publications: 62

Cliona M. Rooney

Cliona M. Rooney

Baylor College of Medicine

Publications: 61

Michael C. Jensen

Michael C. Jensen

Seattle Children's Hospital

Publications: 61

Michael H. Kershaw

Michael H. Kershaw

Peter MacCallum Cancer Centre

Publications: 59

Trending Scientists

Masahiro Fujita

Masahiro Fujita

University of Tokyo

Paul Winters

Paul Winters

University of Notre Dame

Peijun Du

Peijun Du

Nanjing Normal University

Shahram Jadid

Shahram Jadid

Iran University of Science and Technology

Cary T. Chiou

Cary T. Chiou

National Cheng Kung University

Kenneth S. W. Sing

Kenneth S. W. Sing

Brunel University London

Tiangang Luan

Tiangang Luan

Guangdong University of Technology

Mary L. Parker

Mary L. Parker

Norwich University

Tony Ng

Tony Ng

King's College London

José Luis Millán

José Luis Millán

Discovery Institute

Matti Karp

Matti Karp

Tampere University

Hayley Hung

Hayley Hung

Environment and Climate Change Canada

Dominique Valeyre

Dominique Valeyre

Université Paris Cité

Robert H. Brook

Robert H. Brook

RAND Corporation

David T. Mauger

David T. Mauger

Pennsylvania State University

Andreas Eckart

Andreas Eckart

University of Cologne

Something went wrong. Please try again later.